Cytomed TherapeuticsGDTC
13F holders, Q4 2025 (December 31)5holders +3
4new positions
1sold out
$1.33avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, up 3 from Q3 2025. 4 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($40K), Two Sigma Securities, LLC ($16K) and StoneX Group Inc. ($14K).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $69K |
| Exits | 1 | $10K |
All 13F filers, Q3 2025 → Q4 2025: 52,063 shares bought and 17,059 shares sold, net +35,004 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Susquehanna International Group, LLP | 0.00% | New | 29,829 | $40K |
| Two Sigma Securities, LLC | 0.00% | New | 11,857 | $16K |
| StoneX Group Inc. | 0.00% | New | 10,356 | $14K |
| UBS Group AG | 0.00% | Reduce -92.0% | 1,065 | $1K |
| Osaic Holdings, Inc. | 0.00% | New | 21 | $28 |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.